Keros Therapeutics (NASDAQ:KROS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other research analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Leerink Partners cut their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Zacks Research upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $11.61 on Friday. The stock has a fifty day moving average price of $11.13 and a 200-day moving average price of $11.06. The company has a market cap of $230.23 million, a price-to-earnings ratio of -3.14 and a beta of 1.12. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Research analysts predict that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Keros Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that allows the company to buy back $5.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.3% of its stock through open market purchases. Share repurchase plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the transaction, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,343 shares of company stock worth $54,985 over the last 90 days. 12.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Keros Therapeutics in the second quarter valued at approximately $29,898,000. Nantahala Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $15,091,483. Dimensional Fund Advisors LP grew its holdings in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after purchasing an additional 263,347 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Keros Therapeutics in the second quarter worth approximately $2,641,000. Finally, Man Group plc bought a new position in shares of Keros Therapeutics in the second quarter worth approximately $1,664,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. These biological pathways influence blood-cell production, bone health, muscle growth and cardiovascular function, and may play a role in several serious diseases.

The company’s investigational portfolio has included elritercept (KER-050), an engineered ligand trap designed to enhance red blood cell production and address anemia associated with conditions such as myelodysplastic syndromes and myelofibrosis.